Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  TESARO Inc    TSRO

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/22/2017 03/23/2017 03/24/2017 03/27/2017 03/28/2017 Date
155.78(c) 153.62(c) 160(c) 156.73(c) 152.69 Last
733 036 844 857 997 141 1 014 636 2 150 556 Volume
+4.08% -1.39% +4.15% -2.04% -2.58% Change
More quotes
Financials ($)
Sales 2017 94,3 M
EBIT 2017 -408 M
Net income 2017 -421 M
Finance 2017 335 M
Yield 2017 -
Sales 2018 402 M
EBIT 2018 -159 M
Net income 2018 -198 M
Finance 2018 274 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 85,6x
EV / Sales2018 20,2x
Capitalization 8 405 M
More Financials
Company
TESARO, Inc. engages in the research and development of biopharmaceutical products.It focuses on oncology-based therapeutics and consists of the following portfolio: Rolapitant IV and Niraparib.The company was founded by Leon Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010... 
More about the company
Surperformance© ratings of TESARO Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on TESARO INC
05:42p HERE’S WHAT HAPPENED TO TESARO : TSRO) and Foamix Pharmaceuticals Ltd. (NA..
12:23p TESARO : Announces Expanded Development Program for Niraparib Focused on the Tre..
11:11a TESARO : Dishman Pharma zooms 20% as US FDA approves its cancer drug
03/27 TESARO : ANNOUNCES U.S. FDA APPROVAL OF ZEJULA™ (NIRAPARIB) FOR WOMEN WITH..
03/27 TESARO Announces Expanded Development Program for Niraparib Focused on the Tr..
03/17 TESARO : AstraZeneca Fires Back at Tesaro in Ovarian Cancer
03/16 ASTRAZENECA PLC (ADR) (NYSE : AZN)’s Lynparza Trial Results Positive In Co..
03/15 HERE’S WHAT JUST HAPPENED WITH : AZN), TESARO Inc (NASDAQ:TSRO) and Clovis..
03/14 AstraZeneca ovarian cancer drug slows disease markedly in study
03/13 Tesaro Announces Presentation of Niraparib Phase 3 ENGOT-OV16/NOVA Trial Seco..
More news
Sector news : Bio Therapeutic Drugs
06:27pDJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
06:12pDJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
More sector news : Bio Therapeutic Drugs
Latest Tweets
07:57pTesaro Wins One Battle, But Parp War Awaits  
07:30pTesaro Gets Approval For Zejula, Expect U.S. Launch Late April  
06:42pOn The Fly: Top stock stories at midday $F $GM $TSLA $SNAP $FB $DRI $SHLD $TC.. 
06:34p$TSRO non stop $150s test 
06:22pWhy Clovis' Advantage Might Squash Tesaro In Ovarian Cancer  
More tweets
Qtime:34
News from SeekingAlpha
09:14a PREMARKET GAINERS AS OF 9 : 05 am
03/27 After Hours Gainers / Losers
03/27 TESARO to expand development program for PARP inhibitor Zejula; FDA approval ..
03/27 FDA OKs TESARO's niraparib
03/27 Doctors see no clear frontrunner in PARP race; TESARO down 2% on lack of lead..
Advertisement
Chart TESARO INC
Duration : Period :
TESARO Inc Technical Analysis Chart | TSRO | US8815691071 | 4-Traders
Full-screen chart
Technical analysis trends TESARO INC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 186 $
Spread / Average Target 19%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Leon O. Moulder Chief Executive Officer & Director
Mary Lynne Hedley President, Chief Operating Officer & Director
David M. Mott Chairman
Timothy R. Pearson Chief Financial Officer & Executive Vice President
Martin H. Huber Chief Medical Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
TESARO INC16.55%8 405
AMGEN, INC.12.79%121 448
CELGENE CORPORATION7.87%97 137
GILEAD SCIENCES, INC.-5.74%88 227
REGENERON PHARMACEUTIC..4.52%40 701
ACTELION LTD24.40%29 848
More Results